Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000894 · ClinicalTrials.gov registry record · Phase 4

Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis

A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 4
Development phase
300
Enrollment target

NCT00000894: Completed Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000894 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 300 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000894, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 4
Development phase
300 participants
Enrollment target

Study Summary

To compare cidofovir with a commonly used treatment regimen, ganciclovir given by mouth (oral) and through an eye device (intraocular) , in order to determine the safety and effectiveness of cidofovir in preventing vision loss in patients who have AIDS complicated by CMV (cytomegalovirus) retinitis. Cidofovir needs to be compared to ganciclovir to determine the best way to treat CMV retinitis.

Interventions

  • DRUG Probenecid
  • DRUG Cidofovir
  • DRUG Ganciclovir

Trial Details

FieldValue
Enrollment Target 300 participants
Phase Phase 4

What the finished NCT00000894 record still lists

NCT00000894 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower).

The record links to 0 conditions, and to 3 interventions - of which Probenecid is the first listed.

NCT00000894 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000894 about?

NCT00000894 is a clinical study titled "Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis". To compare cidofovir with a commonly used treatment regimen, ganciclovir given by mouth (oral) and through an eye device (intraocular) , in order to determine the safety and effectiveness of cidofovir in preventing vision loss in patients who have AIDS complicated by CMV (cytomegalovirus) retinitis....

What is the current status of trial NCT00000894?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants.

What interventions are being tested in trial NCT00000894?

The interventions under investigation include: Probenecid (DRUG), Cidofovir (DRUG), Ganciclovir (DRUG).

Who is sponsoring clinical trial NCT00000894?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00000894's enrollment target sits among peer trials

300 269th of 2000 higher than 1,709 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Source: ClinicalTrials.gov NCT00000894, the US trial registry maintained by the National Library of Medicine. NCT00000894 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.